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Induction of Autoimmunity in a Bleomycin-Induced
Murine Model of Experimental Systemic Sclerosis:
An Important Role for CD4þ T Cells
Hideaki Ishikawa1,3, Kozue Takeda1, Akira Okamoto2, Sei-ichi Matsuo3 and Ken-ichi Isobe1
Systemic sclerosis (SSc) is an autoimmune disease characterized by the excessive deposition of collagen in the
skin or other organs and the production of specific antinuclear antibodies (ANAs). Recently, bleomycin (BLM)-
induced experimental scleroderma was reported in a murine model. Here, we present further development of
this model and suggest that it is appropriate for the analysis of human diffuse type SSc. BLM was injected into
the shaved backs of C3H or BALB/c mice (100 mg/mouse) 5 days per week for 3 weeks. Skin fibrosis was
confirmed and pathological changes were seen in the lower part of the esophagus and stomach similar to those
seen in SSc. The sera from these mice had autoantibodies specific to the damaged tissues and ANAs. Transfer of
CD4þ T cells from BLM-treated BALB/c mice induced the same pathological changes and antibody production
in untreated-BALB/c nude mice. Hence, tissue fibrosis and the production of ANAs are probably associated with
CD4þ T-cell activity in this model. In conclusion, this model will be valuable for investigating the relationship
between tissue fibrosis and abnormalities of the immune system.
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INTRODUCTION
Systemic sclerosis (SSc) is an autoimmune disease of
connective tissue that is highly heterogeneous in its clinical
manifestations (Abraham and Varga, 2005; Varga and
Abraham, 2007). Although family and twin studies suggest
that a genetic component is important (Arnett et al., 2001),
several environmental factors are believed to be causative
(Nietert and Silver, 2000). There is no established therapy for
SSc. Animal models are needed to reveal the precise
mechanisms of fibrosis and autoimmunity in SSc. Bleomycin
(BLM) is a copper-chelating peptide that can cleave DNA,
and it is widely used as an anti-tumor agent for various types
of malignancies, including squamous cell carcinomas and
lymphoma (Hay et al., 1991; Povirk and Austin, 1991;
Tokuhashi et al., 1997; Burger, 1998). BLM-induced tissue
injury has been extensively studied in a BLM-induced model
of pulmonary fibrosis (Bowden, 1984). Intra-dermal admin-
istration of BLM in mice has been shown to induce skin
fibrosis that closely resembles SSc (Yamamoto et al., 1999;
Lakos et al., 2006; Yamamoto, 2006). Autoantibody produc-
tion was also detectable in this model (Yamamoto et al.,
1999), indicating that BLM treatment induces autoimmunity.
Evidence of autoimmunity has not been described in previous
reports. In this study, we evaluated the pathogenesis of BLM-
induced autoimmunity and determine the potential utility of
this system as a model of human SSc.
RESULTS
Pathological and clinical manifestation of this model
At the site of BLM injection, we found an increase in skin
thickness, a decrease in the amount of subcutaneous fat
tissue, and robust deposition of collagen as determined by
Masson’s trichrome (MaT) (Figure 1a–e). These were the same
histopathological features previously reported for fibrosis
(Yamamoto et al., 1999). Surprisingly, we found BLM-
induced damage at other sites (Figure 1a–e). It can be noted
that, the lower part of the esophagus was affected. We
detected a diminished esophageal wall due to atrophy of the
smooth muscle (Figure 1a–e). In MaT staining of the
esophagus, smooth muscle was stained blue, suggesting that
atrophy of the esophageal smooth muscle was correlated
with fibrosis (Figure 1a–e). We also detected tissue damage in
the stomach where shrinkage of the submucosal layer was
seen (Figure 1a–e). The submucosal layer was rendered blue
by MaT staining (data not shown); hence, this pathological
change was also fibrotic. These tissue changes were measured
and found to be statistically significant (Figure 1c–e). When the
tissue damage found in the dermis of the skin was compared
with that of the esophagus and stomach, we detected some
ORIGINAL ARTICLE
1688 Journal of Investigative Dermatology (2009), Volume 129 & 2009 The Society for Investigative Dermatology
Received 29 July 2008; revised 29 October 2008; accepted 25 November
2008; published online 22 January 2009
1Department of Immunology, Nagoya University Graduate School of
Medicine, Nagoya, Aichi, Japan; 2Department of Molecular Bacteriology,
Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan and
3Department of Nephrology, Nagoya University Graduate School of
Medicine, Nagoya, Aichi, Japan
Correspondence: Dr Ken-ichi Isobe, Department of Immunology, Nagoya
University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku,
Nagoya, Aichi 466-8550, Japan. E-mail: kisobe@med.nagoya-u.ac.jp
Abbreviations: Ab, antibody; ANA, antinuclear antibody; BLM, bleomycin;
MaT, Masson’s trichrome; PBS, phosphate-buffered saline; SSc, systemic
sclerosis
interesting differences. In the skin, increased deposition of
collagen fibers was the primary result. In contrast, in the
esophagus and stomach, fibrosis of the smooth muscle itself
or the submucosal layer was observed. In both cases, these
pathological changes were likely associated with fibrosis.
Fibrosis around a small artery and the interstitium of the
kidney was also observed (data not shown). No apparent
fibrosis in the lung, heart, liver, and small intestine was
observed in C3H mice (data not shown). We also investigated
tissue damage 3 weeks after the termination of BLM
treatment. Interestingly, tissue damage was still observed
(data not shown).
We further evaluated tissue fibrosis by a-smooth muscle
actin staining (see Figure S1). We also compared the
body weights of these two groups. At the conclusion of
BLM treatment, the body weights of the BLM-treated
mice were significantly decreased (Figure 1f). Cytotoxic
effects of BLM may contribute to the loss of body
weights, perhaps associated with the gastric damage shown
in Figure 1e.
Autoantibodies and antinuclear antibody production in this
model
Specific antibodies (Abs), particularly antinuclear antibody
(ANA), are involved in the pathogenesis of human SSc. We
detected the ANA with NIH3T3 and Hep2 targets using sera
from BLM-treated subjects. We concluded that the staining
pattern was anti-nucleolar (Figure 2a–d). Thus, sera from
BLM-treated animals contained ANA, which react with both
murine and human antigens.
400
350
300
250
200
150
100
450
0
*
Control BLM-treated
Control BLM-treated
ControlBLM-treated
Skin H&E
Skin MaT
Esophagus
H&E
Stomach
H&E
Esophagus
MaT
25
20
15
10
5
5
3rd week 6th week
*
*
***
***
*****
**
**
*
*
(µm
)
400
350
300
250
200
150
100
450
0
(µm
)
(µm
)
100
90
80
70
60
50
40
30
20
10
0
(g)
Start
f
Figure 1. Pathogenesis associated with fibrosis in BLM-treated mice. C3H mice were injected subcutaneously with PBS, or 100 mg of BLM (see Materials and
Methods). Representative tissue changes for C3H mice are shown (a–e). (a) Skin H&E and skin MaT, where * indicates dermis of the skin. (b) Esophagus
H&E: long axis, esophagus: short axis, where ** indicates smooth muscle layer of the esophagus. Esophagus MaT: short axis. Fibrotic changes in smooth muscle
were observed. Stomach H&E, where *** indicates submucosal layer of the stomach. Bars¼100 mm. Comparison of (c) the dermis, *Po0.05; (d) smooth muscle
layer, ***Po0.001; and (e) submucosal layer, **Po0.01. Representative comparison data were shown in panels a–e. (f) Time course of body weight changes in
this model. Data are means±SD (control, n¼ 10; BLM-treated, n¼ 10). Body weight loss was observed and it continued even 3 weeks after BLM treatment.
*Po0.05.
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Using sera from BLM-treated mice in western blots,
several bands were detected against every tissue examined
(Figure 3a). Immunofluorescence was also performed on a
stomach section taken from a control mouse (Figure 3b and
c). This result suggests that an autoantibody directed against
the gastric mucosa was present in BLM-treated mice. This
result supports immunoblot data using stomach extracts
(Figure 3a–c). Taken together, we confirmed the extended
production of autoantibodies (including ANAs) after BLM
administration (Figures 2 and 3). These data suggest that
autoantibodies production and gastrointestinal deterioration
reflect BLM-mediated pathogenesis in this model of SSc.
BLM treatment damaged CD4þ T cells
To investigate immune reactions in this model, we examined
the thymus and spleen at different times during and after
treatment. Apparent cytopenia of the thymus and spleen was
observed after BLM administration (Figure 4a–k). Interest-
ingly, in both the thymus and spleen, the number of CD4þ T
cells was significantly decreased, possibly due to cytotoxic
effect of BLM. The size of the thymus was obviously
decreased in the BLM-treated group (Figure 4e). Pathological
analysis showed the destruction of the thymic cortex in
Control serum BLM-treated serum
NIH3T3 NIH3T3Hep2 Hep2
Figure 2. Antinuclear antibodies produced in the model. (a–d) ANAs were
detected using NIH3T3 and Hep2 targets. The staining pattern in Hep2 is
recognizable as an antinucleolar pattern (b and d). Bars¼ 50mm. Data are
representative of three separate experiments.
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Figure 3. Autoantibodies in sera from BLM-treated mice. (a) Tissue antigens detected by western blotting. Serum samples (10ml) were taken the day following
the final BLM treatment (day 22), six mice per group. Protein samples were prepared as described in Materials and Methods. (b and c) Antibodies to normal
stomach were detected. Bar¼100 mm. Representative data from several independent experiments are shown.
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Figure 4. BLM-induced damage to the thymus and spleen. (a–e) Significant decrease in CD4þ T cells in the thymus. Thymus from (a) control and (b) BLM-
treated mice. (c) Comparison of total thymocytes. (d) Comparison of CD4þCD8 cells. Data are means±SD (control, n¼ 4; BLM-treated, n¼ 4). Representative
of three separate experiments. (e) Atrophy of the thymus in BLM-treated mice. (f–j) Significant decrease in CD4þ T cells in the spleen. Splenocytes from (f, i)
control, and (g, j) BLM-treated mice. (h) Comparison of CD3þ cells. (k) Comparison of CD4þCD8 cells. Data are means±SD (control, n¼4; BLM-treated,
n¼ 4). *Po0.05; **Po0.01; and ***Po0.001. Representative of three separate experiments.
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BLM-treated mice (data not shown). This result suggests that
BLM might have inhibited CD4þ T cells’ maturation. In the
spleen, the total number of T cells was significantly reduced
due to decreasing numbers of CD4þ T cells (Figure 4f–k).
Taken together, these data suggested that CD4þ T cells are
particularly susceptible to the effects of BLM in both the
thymus and spleen. The sensitivity of CD4þ T cells may be
associated with the induction of autoimmunity in this model.
Adaptive cell transfer of BLM-treated lymphocytes reproduce
tissue fibrosis
Our results (Figures 2 and 3) suggest the presence of an
autoimmune response in BLM-treated mice. We postulated
that splenocytes of BLM-treated mice included a population
of autoimmune T cells, and therefore the adaptive cell
transfer was performed. The experimental design for this
experiment is described in the Materials and Methods
section. We observed increased collagen fibers in the dermis
of the skin in BALB/c and C3H mice. Hypertrophy of the
gastric mucosa was also induced in BLM-treated BALB/c
mice (Figure 5a and b). Interestingly, nearly the same tissue
changes were present in the recipient mice and BLM-treated
donors (Figure 5c and d). No tissue changes were found in
control donor mice (Figure 5e and f; PBS-treated BALB/c
mice), and no tissue changes were induced in the recipient
mice (Figure 5g and h). Taken together, we confirmed that
skin fibrosis and fibrotic gastritis were directly induced by
BLM-induced autoreactive lymphocytes.
CD4 þ T cells play a key role for tissue change and
autoimmunity in this experimental model
We showed the existence of autoreactive lymphocytes in the
experiments shown in Figure 5. We next asked what type of
lymphocytes was essential for producing these pathological
changes and autoimmunity. Thus, we compared the effects of
CD4þ T cells and B cells. Purification of CD4þ T cells was
performed as described in Materials and Methods. The purity
was 490%, which was sufficient to ignore the contribution
of lymphocytes other than CD4þ T cells (Figure 6a). We
found that the transfer of 106 fractionated spleen cells taken
from BLM-treated mice produced nearly the same patholo-
gical changes observed with total cells (Figure 6b, c, and e).
In this experiment, we also analyzed autoantibody produc-
tion and observed virtually the same pattern of ANA after
CD4þ T cells were transferred to nude mice. The purity of B
cells was also over 90% (Figure 6h–n). B cells (106) taken
from the BLM-treated donor mouse failed to reproduce the
same pathological changes (Figure 6i, j, l, and m). Although
ANA was found in the donor mouse, it was not detected in
the recipient mouse (Figure 6d and g). Taken together, we
conclude that CD4þ T cells, but not B cells in the BLM-
treated mice induced the observed pathological changes and
autoimmunity.
DISCUSSION
Our data indicated that continuous BLM administration
induces tissue fibrosis and initiates autoimmunity. It can be
noted that, we found esophageal and gastric damage related
to fibrosis. Pathogenesis in our model was quite similar to
SSc. Interestingly, autoantibodies, including ANAs, were also
detectable. Most importantly, we verified that CD4þ T cells
play a central role in the induction of tissue fibrosis and
autoimmunity (Figure 6). Although we used a previously
published procedure to induce experimental scleroderma
(Yamamoto et al., 1999), to the best of our knowledge, this is
the first report showing gastrointestinal involvement and
suggesting a possible mechanism underlying the autoimmu-
nity observed in this model.
In established murine models of systemic lupus erythe-
matosus, such as MRL/lpr or NZB/W mice, genetic factors
contribute to the onset of disease (Knight and Adams, 1981;
Itoh et al., 1994), and autoimmunity develops spontaneously.
We successfully induced experimental SSc in both C3H and
BALB/c mice. These findings suggest that BLM-mediated
pathology is at least partially independent of genetic back-
ground. Although genetic abnormalities contribute to auto-
immune diseases, environmental risk factors are also
responsible (Anderson and Warner, 1976). BLM is a
glycopeptide–polypeptide from Streptomyces verticillus that
induces sequence-selective oxidative damage to nucleic
BLM-treated donor mouse Recipient nude mouse
Recipient nude mouseControl donor mouse
Figure 5. Reproduction of autoimmune pathology by transfer of splenocytes
from BLM-treated mice. (a) Skin and (b) stomach samples taken from BLM-
treated donor mouse. Dermal skin thickening and proliferation of gastric
mucosa were observed. (c) Skin and (d) stomach samples taken from recipient
nude mouse. Nearly the same changes were detected in these tissues. (e) Skin
and (f) stomach samples taken from control mouse. No damage was seen in
these tissues. (g) Skin and (h) stomach samples taken from recipient nude
mouse. No tissue changes were detected. Scale bar¼ 100mm. All sections
stained with H&E. Representative data from three independent experiments.
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acids (Burger, 1998). Furthermore, oxidative stress plays a
role triggering autoimmunity (Kovacic and Jacintho, 2003).
Previous studies reported that an environmental factor might
be involved in the etiology of SSc (Bovenzi et al., 2004; Gold
et al., 2007). Our results support the idea that certain
chemical agents may increase the risk of SSc.
Involvement of the gastrointestinal tract is the second most
common manifestation of SSc. Over 80% of patients
experience a change in normal gastrointestinal function
(LeRoy et al., 1988; Roberts et al., 2006). Recent studies
reported the pathogenesis of the esophagus and stomach in
SSc patients (Szamosi et al., 2006; Domsic et al., 2008). They
suggested that smooth muscle atrophy in the esophagus and
fibrotic involvement of the gastric wall may account for
stomach hypomotility in SSc. In our model, both the atrophic
change in the esophageal wall and fibrosis of the submucosal
layer of the stomach were observed. These data are consistent
with the pathogenesis observed in SSc.
The presence of autoantibodies is a central feature of
immune activation in SSc. SSc patients have autoantibodies
that react to various intracellular components, such as DNA
topoisomerase I, centromeres, RNA polymerases, U1RNP,
U3RNP and Th/To, and histones (Okano, 1996). Certain Abs
are characteristic of SSc, such as anti-nucleolar and anti-
centromere Abs and Abs to the soluble nuclear antigen Scl-
70. In our model, we confirmed the existence of specific
ANAs by immunofluorescence (Figure 2). The role of
autoantibodies, including ANAs in SSc, might well be
important, though their significance remains unclear (Cepeda
and Reveille, 2004). The relationship between the emergence
of autoantibodies and fibrotic and vascular manifestations of
SSc is not understood despite recent studies, suggesting that
the titers of some of these autoantibodies may correlate with
disease activity and clinical severity (Hu et al., 2003). In our
experiments, we detected autoantibodies that strongly
reacted with the gastric mucosa (Figure 3). Hence, we
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Figure 6. CD4þ T cells but not B cells play a role in the induction of pathogenesis and autoimmunity in this model. (a–g) CD4þ T cells were purified by MACS
as described in Materials and Methods. (a) Purity was490%. (b, c) Four weeks after transfer, pathological changes were evaluated. Tissue sections from the skin
and stomach were stained with H&E. (e, f) Purified CD4þ cells (106) from BLM-treated BALB/c mice induced similar tissue damage (H&E, original
magnification,  100). The same pattern of ANA was detected in both donor mice (d) and recipient mice (g). (h–n) B cells (106) were also purified by MACS. (a)
Purity was490%. (i, j, l, and m) Despite significant pathology in the donor mouse, no tissue changes were detected in the recipient nude mouse. In addition to
the pathological findings, ANA was not seen in the recipient mouse. Bars¼ 100 mm. Representative data from three independent experiments in panels a–n.
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speculate that the production of these autoantibodies might
be associated with pathogenesis in the gastrointestinal tract.
The relationship between autoantibodies and pathogenesis in
SSc will be analyzed in upcoming studies.
Several findings support the role of homeostatic anti-self T-
cell proliferation in the pathogenesis of autoimmunity.
Ionizing radiation can alter the immune system and break
self-tolerance (Sakaguchi et al., 1994). The exact mechan-
isms, which regulate the proliferation of anti-self peripheral
T cells, are not fully understood. Nevertheless, evidence
exists that self-MHC/peptide recognition may be seriously
affected under certain conditions such as lymphopenia. We
speculate that severe CD4þ T-cell lymphopenia mediated by
BLM is possibly the primary trigger for the autoimmune
reaction in this model (Figure 4). Hence, we hypothesize that
investigations focusing on the role of CD4þ T cells might
clarify the mechanisms of autoimmune pathology in SSc.
In our model, experimental SSc was partially reproduced
by autoreactive CD4þ T-cell transfer. Interestingly, B-cell
transfer failed to reproduce these phenomena. Therefore,
BLM-induced autoimmunity is partially mediated by acti-
vated autoreactive CD4þ T cells. In donor mice, it was
difficult to clearly separate the pathological changes induced
directly by BLM from those by immunized lymphocytes.
However, the characteristic pathological changes such as
fibrosis of tissues and ANA production in recipient nude mice
are mediated by ‘‘autoreactive CD4þ T cells’’ derived by
BLM treatment (Figures 5 and 6).
Recent studies have shown that autoreactive CD4þ T cells
play a key role in the induction of autoimmunity (Rankin
et al., 2008). The details of the mechanism are of ongoing
interest. Accumulating evidence implicates cytokine net-
works for initiating, and either propagating or terminating
fibroblast activation. Previous work investigated the possible
role of Th1 and Th2 cytokines in the pathogenesis of fibrosis
in an experimental animal model (Lakos et al., 2006). We
investigated cytokine profiles in our model and found that IL-
17 release appeared to be upregulated in BLM-treated murine
CD4þ T cells (see Figure S2). IL-17 may be related to the
induction of autoimmunity, including SSc (Stockinger et al.,
2007; Bettelli et al., 2008; Murata et al., 2008; Rueda et al.,
2008). Finally, there is accumulating evidence regarding the
involvement of CD4þ T cells in SSc (Alaibac et al., 2006;
Deleuran and Abraham, 2007; Parel et al., 2007).
In conclusion, a mouse model of experimental SSc is not
currently available. Our model possesses clinically significant
features of SSc in humans and the pathology is relatively easy to
induce. Our findings suggest that an environmental factor such
as a chemical (BLM in this case) might be a trigger for
autoimmune disease. Fibrosis and the induction of autoimmu-
nity by autoreactive CD4þ T cells in this model also merit
detailed analyses. Further research with this model will fulfill an
experimental need for tools to explore SSc in humans.
MATERIALS AND METHODS
Animals
Pathogen-free, female C3H/HeJ, BALB/c, and BALB/c nude
mice (6 weeks old; weight about 20 g) were purchased from SLC
(Shizuoka, Japan). The Animal Care and Ethics committee of Nagoya
University approved the care of mice and the experimental
procedures.
BLM treatment
BLM (Nippon Kayaku Co. Ltd, Tokyo, Japan) was dissolved
in phosphate-buffered saline (PBS) at a concentration of 1mgml1.
A volume of 100ml of BLM or control PBS was injected
subcutaneously with a 26-gauge needle into the shaved
backs of mice 5 days per week for 3 consecutive weeks. After
the final BLM or PBS injection, mice were observed without any
additional treatment for an additional 3 weeks. The total experi-
mental period was 6 weeks (42 days). There were 30–40 mice in
each group (PBS or BLM). Tissue analysis and, serum and cell
analyses shown in the Results section were performed the day
following the final PBS or BLM treatment (on day 22) unless
indicated otherwise.
Histological analyses
Tissues from the skin, lung, heart, esophagus, stomach, small
intestine, liver, and spleen were removed the day following the
final PBS or BLM injection (day 22). Paraffin sections were stained
with either hematoxylin and eosin or MaT to evaluate histopatho-
logical changes and to detect collagen fibers in tissues. The
quantitative analysis of tissues was performed as described earlier
(Koca et al., 2008; Liu et al., 2008; Szabo et al., 2008). Ice-cold,
acetone-fixed cryosections (5mm) were prepared using a cryostat
(Tissue-Tek OCT, Sakura Finetec, Torrance, CA, USA) and stored at
–20 1C until stained for immunohistochemistry, which was per-
formed according to the established methods. Sections were
examined using a light microscope and photographed with a digital
camera (Carl Zeiss Shinjuku-ku, Tokyo, Japan).
Autoantibody detection
Tissues and cells were lysed in the sample buffer (62.5mM Tris-HCl,
pH 6.8, 2% SDS, 10% glycerol, 5% 2-mercaptoethanol, and 5%
bromophenol blue). Samples (1mgml1 total protein) were sepa-
rated by electrophoresis in SDS-containing (12.5%) polyacrylamide
gels and then transferred to polyvinylidene difluoride membranes
(Millipore Corporation Bedford, MA). The same amount of protein
was prepared for each organ. Blotted membranes were treated with
1:100 diluted serum from BLM-treated mice or control mice. The
membranes were then reacted with 1:1,000 diluted horseradish
peroxidase-conjugated goat IgG fraction against mouse IgG (Cappel,
Durham, NC) as a secondary Ab. Detection used an enhanced
chemiluminescence system (GE Healthcare Bio-Sciences Tokyo,
Japan). ANAs were detected by indirect immunofluorescence
methods using murine NIH3T3 cells and human Hep-2 cells (RIKEN
BioResource Center, Ibaraki, Japan). Cryostat sections of control
gastric mucosa were also used to detect autoantibodies. Both
NIH3T3 and Hep-2 cells were grown on Chamber Slides (Lab-Tek,
Nalge Nunc International, NY, USA) and fixed using 20 1C ethanol.
Murine sera (diluted 1:100) from each group were incubated on the
slides, followed by detection with FITC-labeled rabbit anti-mouse
IgG (1:100 dilution; Invitrogen Immunodetection, San Francisco,
CA, USA) according to the manufacturer’s instructions. The sera
from mice were stocked at 80 1C before staining.
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Flow cytometry
Abs described below and reagents used in flow cytometry were
purchased from eBioscience (San Diego, CA). Thymocytes and
splenocytes were harvested on day 22 and stained on ice with
appropriate Ab dilutions in PBS containing 0.02% sodium azide and
0.5% BSA, using FITC-conjugated anti-CD4 mAb, anti-CD3 mAb, anti-
CD8 mAb, phycoerythrin (PE)-conjugated anti-CD45RB220 mAb, anti-
CD8 mAb, and anti-CD4 mAb. Cells were assessed on a flow
cytometer (FACS Calibur, Becton Dickinson, Tokyo, Japan), and
analyzed using FlowJo software (Tomy Digital Biology, Tokyo, Japan).
Cell transfer
To determine whether autoreactive B or CD4þ T lymphocytes were
present in our model, and whether they induced tissue damage,
splenocytes of BLM-treated BALB/c mice were injected intrave-
nously into age-matched BALB/c nude mice. The aim of this
experiment was to determine whether lymphocytes from BLM-
treated mice would induce tissue fibrosis and ANA production in
recipient mice. Cell donors from BLM-treated mice and PBS-treated
(control) mice were killed the day after the final injection (day 22)
and their spleens were removed. Spleens were placed in 6–7ml of
cold PBS/2% FBS and cut into small pieces, disaggregated by
aspiration, and filtered. After three cold washes by centrifugation,
the cells were resuspended in 5ml PBS/2% FBS. Cells (106) were
resuspended in 100ml of PBS for injection into recipient BALB/c
nude mice. For additional transfer experiments, donor mouse
splenocytes were purified for B or CD4þ T cells by ‘‘negative
selection.’’ CD4þ T cells were purified with the negative selection
kit (CD4 T Cell Isolation Kit, Miltenyi-Biotec, Tokyo, Japan) using a
MACS Column (LS column). For B-cell purification, we used the B
Cell Isolation Kit. The magnetically labeled non-T cells or non-B
cells are depleted by retention on the MACS Column (LS column) in
the magnetic field of an MACS Separator, whereas the unlabeled
CD4 T cells or B cells pass through the column. Finally, purified B
cells or CD4þ T cells (106) were washed three times at 4 1C and
resuspended in 100ml of PBS and then injected intravenously into
recipient BALB/c nude mice. The purities of enriched B cells and
CD4þ T cells were evaluated by flow cytometric analysis.
Representative comparisons are shown in Figure 6. Four weeks after
cell transfer, skin and stomach tissues of recipient mice were taken
for pathological analysis. These tissues have characteristic clinical
signs of SSc for BALB/c mice. Sera of recipient mice were pooled to
detect ANA. Five donors and five recipient mice of each group were
used for each experiment, which was done three times (data from
one representative experiment are given in the Results section).
Statistical data analysis
Results were expressed as means±SD. Statistical data analysis was
performed using StatView software (Hulinks Inc., Tokyo, Japan).
Significance was determined by the Mann–WhitneyU-test. A P-value
o0.05 was considered significant.
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